Video Experimental Relacionado
Updated: Jul 6, 2026
06:23
Visualizing Axonal Growth Cone Collapse and Early Amyloid β Effects in Cultured Mouse Neurons
Published on: October 30, 2018
100 años y contando: perspectivas para derrotar la enfermedad de Alzheimer
Erik D Roberson1, Lennart Mucke
1Gladstone Institute of Neurological Disease and Department of Neurology, University of California, San Francisco, CA 94158, USA.
Science (New York, N.Y.)
|November 4, 2006
Resumen
La enfermedad de Alzheimer (EA) sigue siendo una condición devastadora a pesar de los tratamientos actuales. Prometedoras nuevas terapias dirigidas a la beta-amiloide, la tau y la vulnerabilidad neuronal se encuentran en ensayos clínicos, lo que ofrece esperanza para mejorar los tratamientos de la enfermedad de Alzheimer.
Área de la Ciencia:
- La neurociencia es la neurociencia.
- Gerontología Gerontología.
- Farmacología Farmacología.
Sus antecedentes:
- La enfermedad de Alzheimer (EA) se conoce desde hace un siglo, sin embargo, sigue siendo una de las principales causas de pérdida de memoria y muerte.
- Los medicamentos actuales para la EA ofrecen una eficacia limitada, lo que pone de relieve la necesidad urgente de nuevas estrategias terapéuticas.
- Se prevé que la prevalencia de la EA aumente significativamente en las próximas décadas.
Objetivo del estudio:
- Revisar el panorama actual de las terapias de la enfermedad de Alzheimer en desarrollo clínico.
- Para resaltar los objetivos y estrategias terapéuticas emergentes para el tratamiento de la EA.
- Subrayar la urgencia de desarrollar intervenciones más efectivas para el Alzheimer.
Principales métodos:
- Revisión de los ensayos clínicos en curso para las terapias de la enfermedad de Alzheimer.
- Análisis de investigaciones emergentes sobre la patogénesis de la EA, incluidos el beta-amiloide, el tau y la apolipoproteína E.
- Exploración de nuevos conocimientos sobre la vulnerabilidad neuronal y la conexión envejecimiento-AD.
Principales resultados:
- Múltiples estrategias terapéuticas dirigidas a los péptidos beta amiloide patogénicos se encuentran en ensayos clínicos.
- Se están investigando enfoques para proteger las neuronas vulnerables de la degeneración.
- Las estrategias emergentes se centran en las funciones copatogénicas de la apolipoproteína E y la tau, junto con los factores relacionados con el envejecimiento.
Conclusiones:
- La tubería de terapias para la enfermedad de Alzheimer se está expandiendo con diversos enfoques basados en mecanismos.
- Dirigirse a la beta amiloide, la tau y la vulnerabilidad neuronal ofrece vías prometedoras para futuros tratamientos de la enfermedad de Alzheimer.
- El desarrollo acelerado de terapias efectivas para la enfermedad de Alzheimer es crítico debido a la creciente carga global de la enfermedad.
Más Videos Relacionados
09:00Biochemical Purification and Proteomic Characterization of Amyloid Fibril Cores from the Brain
Published on: April 28, 2022
09:47DeepOmicsAE: Representing Signaling Modules in Alzheimer's Disease with Deep Learning Analysis of Proteomics, Metabolomics, and Clinical Data
Published on: December 15, 2023
Videos de Conceptos Relacionados
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:21Huntington Disease l: Introduction
Huntington disease or HD is a progressive, fatal neurodegenerative disorder inherited in an autosomal dominant pattern.PathophysiologyIt is caused by expansion of the CAG trinucleotide repeat in the HTT gene on chromosome 4 (4p16.3), producing an abnormal huntingtin protein with an expanded polyglutamine tract. This misfolded protein disrupts cellular function, leading to neuronal death. Normal alleles have ≤26 repeats, 27–35 are intermediate (risk of expansion), 36–39 show reduced penetrance,...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...